Novel immunosuppressant agents targeting activated lymphocytes by biocompatible MPC polymer conjugated with interleukin-2

N. Chiba, M. Ueda, T. Shimada, H. Jinno, J. Watanabe, K. Ishihara, M. Kitajima

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The immunopharmacological profile of novel biocompatible water-soluble interleukin-2 (IL-2)-conjugated 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer immunosuppressive agents was established. MPC-co-n- butyl methacrylate (BMA)-co-p-nitrophenylcarbonyloxyethyl methacrylate (NPMA) (PMBN) was prepared as a backbone for these novel agents. PMBN contained MPC as a biocompatible unit, BMA as a hydrophobic domain in water, and NPMA as an immobilizable unit with IL-2. This research showed that proliferation of cell lines with high-affinity IL-2 receptors derived from T cell malignancies were suppressed by the PMBN conjugated with IL-2 (PMBN-IL2 conjugate) incorporating paclitaxel (PTX) and cyclosporin A at lower concentrations than used conventionally. PMBN-IL2 conjugates incorporating PTX also inhibited the proliferation of responder cells in a human mixed lymphocyte culture at a lower concentration than unconjugated drug. However, PMBN-IL2 conjugates incorporating FK506 inhibited proliferation no more than FK506 alone. The PMBN-IL2 conjugate with PTX may therefore be useful for selectively eliminating activated lymphocytes that hyperproduce high-affinity IL-2 receptors. As an entirely human 'immunotoxin analogue' it may not be associated with the dose-limiting toxicity and immunogenicity of conventional immunotoxins.

Original languageEnglish
Pages (from-to)103-110
Number of pages8
JournalEuropean Surgical Research
Volume39
Issue number2
DOIs
Publication statusPublished - 2007 Mar

Fingerprint

Phosphorylcholine
Immunosuppressive Agents
Interleukin-2
Polymers
Lymphocytes
Paclitaxel
Immunotoxins
Methacrylates
Interleukin-2 Receptors
Tacrolimus
Water
polymyxin B nonapeptide
Cyclosporine
Cell Proliferation
T-Lymphocytes
Cell Line
Research
Pharmaceutical Preparations
Neoplasms

Keywords

  • Immunosuppressive agents
  • Interleukin-2
  • Interleukin-2 receptor, high affinity
  • MPC polymer

ASJC Scopus subject areas

  • Surgery

Cite this

Novel immunosuppressant agents targeting activated lymphocytes by biocompatible MPC polymer conjugated with interleukin-2. / Chiba, N.; Ueda, M.; Shimada, T.; Jinno, H.; Watanabe, J.; Ishihara, K.; Kitajima, M.

In: European Surgical Research, Vol. 39, No. 2, 03.2007, p. 103-110.

Research output: Contribution to journalArticle

Chiba, N, Ueda, M, Shimada, T, Jinno, H, Watanabe, J, Ishihara, K & Kitajima, M 2007, 'Novel immunosuppressant agents targeting activated lymphocytes by biocompatible MPC polymer conjugated with interleukin-2', European Surgical Research, vol. 39, no. 2, pp. 103-110. https://doi.org/10.1159/000099598
Chiba, N. ; Ueda, M. ; Shimada, T. ; Jinno, H. ; Watanabe, J. ; Ishihara, K. ; Kitajima, M. / Novel immunosuppressant agents targeting activated lymphocytes by biocompatible MPC polymer conjugated with interleukin-2. In: European Surgical Research. 2007 ; Vol. 39, No. 2. pp. 103-110.
@article{6013f9e6378c41389770f0bcce167071,
title = "Novel immunosuppressant agents targeting activated lymphocytes by biocompatible MPC polymer conjugated with interleukin-2",
abstract = "The immunopharmacological profile of novel biocompatible water-soluble interleukin-2 (IL-2)-conjugated 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer immunosuppressive agents was established. MPC-co-n- butyl methacrylate (BMA)-co-p-nitrophenylcarbonyloxyethyl methacrylate (NPMA) (PMBN) was prepared as a backbone for these novel agents. PMBN contained MPC as a biocompatible unit, BMA as a hydrophobic domain in water, and NPMA as an immobilizable unit with IL-2. This research showed that proliferation of cell lines with high-affinity IL-2 receptors derived from T cell malignancies were suppressed by the PMBN conjugated with IL-2 (PMBN-IL2 conjugate) incorporating paclitaxel (PTX) and cyclosporin A at lower concentrations than used conventionally. PMBN-IL2 conjugates incorporating PTX also inhibited the proliferation of responder cells in a human mixed lymphocyte culture at a lower concentration than unconjugated drug. However, PMBN-IL2 conjugates incorporating FK506 inhibited proliferation no more than FK506 alone. The PMBN-IL2 conjugate with PTX may therefore be useful for selectively eliminating activated lymphocytes that hyperproduce high-affinity IL-2 receptors. As an entirely human 'immunotoxin analogue' it may not be associated with the dose-limiting toxicity and immunogenicity of conventional immunotoxins.",
keywords = "Immunosuppressive agents, Interleukin-2, Interleukin-2 receptor, high affinity, MPC polymer",
author = "N. Chiba and M. Ueda and T. Shimada and H. Jinno and J. Watanabe and K. Ishihara and M. Kitajima",
year = "2007",
month = "3",
doi = "10.1159/000099598",
language = "English",
volume = "39",
pages = "103--110",
journal = "European Surgical Research",
issn = "0014-312X",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Novel immunosuppressant agents targeting activated lymphocytes by biocompatible MPC polymer conjugated with interleukin-2

AU - Chiba, N.

AU - Ueda, M.

AU - Shimada, T.

AU - Jinno, H.

AU - Watanabe, J.

AU - Ishihara, K.

AU - Kitajima, M.

PY - 2007/3

Y1 - 2007/3

N2 - The immunopharmacological profile of novel biocompatible water-soluble interleukin-2 (IL-2)-conjugated 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer immunosuppressive agents was established. MPC-co-n- butyl methacrylate (BMA)-co-p-nitrophenylcarbonyloxyethyl methacrylate (NPMA) (PMBN) was prepared as a backbone for these novel agents. PMBN contained MPC as a biocompatible unit, BMA as a hydrophobic domain in water, and NPMA as an immobilizable unit with IL-2. This research showed that proliferation of cell lines with high-affinity IL-2 receptors derived from T cell malignancies were suppressed by the PMBN conjugated with IL-2 (PMBN-IL2 conjugate) incorporating paclitaxel (PTX) and cyclosporin A at lower concentrations than used conventionally. PMBN-IL2 conjugates incorporating PTX also inhibited the proliferation of responder cells in a human mixed lymphocyte culture at a lower concentration than unconjugated drug. However, PMBN-IL2 conjugates incorporating FK506 inhibited proliferation no more than FK506 alone. The PMBN-IL2 conjugate with PTX may therefore be useful for selectively eliminating activated lymphocytes that hyperproduce high-affinity IL-2 receptors. As an entirely human 'immunotoxin analogue' it may not be associated with the dose-limiting toxicity and immunogenicity of conventional immunotoxins.

AB - The immunopharmacological profile of novel biocompatible water-soluble interleukin-2 (IL-2)-conjugated 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer immunosuppressive agents was established. MPC-co-n- butyl methacrylate (BMA)-co-p-nitrophenylcarbonyloxyethyl methacrylate (NPMA) (PMBN) was prepared as a backbone for these novel agents. PMBN contained MPC as a biocompatible unit, BMA as a hydrophobic domain in water, and NPMA as an immobilizable unit with IL-2. This research showed that proliferation of cell lines with high-affinity IL-2 receptors derived from T cell malignancies were suppressed by the PMBN conjugated with IL-2 (PMBN-IL2 conjugate) incorporating paclitaxel (PTX) and cyclosporin A at lower concentrations than used conventionally. PMBN-IL2 conjugates incorporating PTX also inhibited the proliferation of responder cells in a human mixed lymphocyte culture at a lower concentration than unconjugated drug. However, PMBN-IL2 conjugates incorporating FK506 inhibited proliferation no more than FK506 alone. The PMBN-IL2 conjugate with PTX may therefore be useful for selectively eliminating activated lymphocytes that hyperproduce high-affinity IL-2 receptors. As an entirely human 'immunotoxin analogue' it may not be associated with the dose-limiting toxicity and immunogenicity of conventional immunotoxins.

KW - Immunosuppressive agents

KW - Interleukin-2

KW - Interleukin-2 receptor, high affinity

KW - MPC polymer

UR - http://www.scopus.com/inward/record.url?scp=34047096932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047096932&partnerID=8YFLogxK

U2 - 10.1159/000099598

DO - 10.1159/000099598

M3 - Article

C2 - 17299267

AN - SCOPUS:34047096932

VL - 39

SP - 103

EP - 110

JO - European Surgical Research

JF - European Surgical Research

SN - 0014-312X

IS - 2

ER -